CN117069836A - Preparation method of anti-human T cell rabbit immunoglobulin - Google Patents
Preparation method of anti-human T cell rabbit immunoglobulin Download PDFInfo
- Publication number
- CN117069836A CN117069836A CN202311241053.8A CN202311241053A CN117069836A CN 117069836 A CN117069836 A CN 117069836A CN 202311241053 A CN202311241053 A CN 202311241053A CN 117069836 A CN117069836 A CN 117069836A
- Authority
- CN
- China
- Prior art keywords
- human
- placenta
- plasma
- hydroformylation
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000283973 Oryctolagus cuniculus Species 0.000 title claims abstract description 59
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 45
- 108060003951 Immunoglobulin Proteins 0.000 title claims abstract description 42
- 102000018358 immunoglobulin Human genes 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 210000002381 plasma Anatomy 0.000 claims abstract description 38
- 210000002826 placenta Anatomy 0.000 claims abstract description 36
- 238000000034 method Methods 0.000 claims abstract description 34
- 238000007037 hydroformylation reaction Methods 0.000 claims abstract description 24
- 238000004255 ion exchange chromatography Methods 0.000 claims abstract description 20
- 210000004027 cell Anatomy 0.000 claims abstract description 15
- 238000001514 detection method Methods 0.000 claims abstract description 14
- 239000000047 product Substances 0.000 claims abstract description 14
- 210000003743 erythrocyte Anatomy 0.000 claims abstract description 10
- 210000001541 thymus gland Anatomy 0.000 claims abstract description 9
- 238000001042 affinity chromatography Methods 0.000 claims abstract description 8
- 210000002966 serum Anatomy 0.000 claims abstract description 8
- 239000000539 dimer Substances 0.000 claims abstract description 6
- 239000000178 monomer Substances 0.000 claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 210000005259 peripheral blood Anatomy 0.000 claims abstract description 3
- 239000011886 peripheral blood Substances 0.000 claims abstract description 3
- 239000007788 liquid Substances 0.000 claims description 33
- 239000000243 solution Substances 0.000 claims description 32
- 230000003053 immunization Effects 0.000 claims description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 22
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 108090000623 proteins and genes Proteins 0.000 claims description 22
- 238000002649 immunization Methods 0.000 claims description 20
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 18
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 18
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 17
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 239000006228 supernatant Substances 0.000 claims description 13
- 210000004698 lymphocyte Anatomy 0.000 claims description 12
- 239000011780 sodium chloride Substances 0.000 claims description 11
- 239000004471 Glycine Substances 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- 238000006386 neutralization reaction Methods 0.000 claims description 9
- 241000700605 Viruses Species 0.000 claims description 8
- 239000008055 phosphate buffer solution Substances 0.000 claims description 8
- 239000011265 semifinished product Substances 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 8
- 239000002893 slag Substances 0.000 claims description 7
- 238000012360 testing method Methods 0.000 claims description 7
- 239000012528 membrane Substances 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 238000007920 subcutaneous administration Methods 0.000 claims description 6
- 108090000542 Lymphotoxin-alpha Proteins 0.000 claims description 5
- 102000004083 Lymphotoxin-alpha Human genes 0.000 claims description 5
- 239000003480 eluent Substances 0.000 claims description 5
- 238000011068 loading method Methods 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 238000002844 melting Methods 0.000 claims description 4
- 230000008018 melting Effects 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000000108 ultra-filtration Methods 0.000 claims description 4
- 102000004506 Blood Proteins Human genes 0.000 claims description 3
- 108010017384 Blood Proteins Proteins 0.000 claims description 3
- 101710154606 Hemagglutinin Proteins 0.000 claims description 3
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 3
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 3
- 101710176177 Protein A56 Proteins 0.000 claims description 3
- 241000220317 Rosa Species 0.000 claims description 3
- 239000008351 acetate buffer Substances 0.000 claims description 3
- 238000011118 depth filtration Methods 0.000 claims description 3
- 238000006073 displacement reaction Methods 0.000 claims description 3
- 239000002158 endotoxin Substances 0.000 claims description 3
- 239000000185 hemagglutinin Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 238000010253 intravenous injection Methods 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 238000007363 ring formation reaction Methods 0.000 claims description 3
- 238000010257 thawing Methods 0.000 claims description 3
- 230000003169 placental effect Effects 0.000 claims description 2
- 239000011148 porous material Substances 0.000 claims description 2
- 239000002002 slurry Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 abstract description 8
- 239000012535 impurity Substances 0.000 abstract description 6
- 238000000746 purification Methods 0.000 abstract description 4
- 229910052782 aluminium Inorganic materials 0.000 abstract description 3
- 239000012467 final product Substances 0.000 abstract description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 abstract 1
- 238000007086 side reaction Methods 0.000 abstract 1
- 238000004458 analytical method Methods 0.000 description 11
- 239000000427 antigen Substances 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 3
- 238000010241 blood sampling Methods 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000003916 acid precipitation Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- -1 aluminum ions Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000001994 activation Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000009189 diving Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002906 medical waste Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention relates to the technical field of biological products, in particular to a preparation method of anti-human T cell rabbit immunoglobulin. The method is that the rabbit plasma or serum immunized by human peripheral blood T lymphocytes and/or thymus cells is firstly absorbed by hydroformylation human erythrocytes and hydroformylation human placenta and then is sequentially subjected to first ion exchange chromatography, affinity chromatography and second ion exchange chromatography to prepare the anti-human T cell rabbit immunoglobulin which meets the standards of anti-human T cell rabbit immunoglobulin in the current edition of Chinese pharmacopoeia, and the molecular size purity detection result (monomer and dimer) of the final product can reach 100 percent, basically has no obvious impurity and is far higher than the standards of more than 90 percent in the current edition of Chinese pharmacopoeia. The purification method can not introduce aluminum and other impurities which are easy to cause clinical side reactions, has good process continuity, can well realize digital and automatic control, and is used for amplified production.
Description
Technical Field
The invention relates to the technical field of biological products, in particular to a preparation method of anti-human T cell rabbit immunoglobulin.
Background
Anti-human T-cell immunoglobulin (ATG) is a strong immunosuppressant, can inhibit lymphocyte activation process after antigen recognition, specifically destroy lymphocytes, and is mainly used for preventing and treating rejection reaction of organ inhibition, treating hormone tolerance and graft versus host disease and treating aplastic anemia in medical treatment.
The existing anti-human T cell immunoglobulin is mainly two kinds, namely anti-human T cell pig immunoglobulin and anti-human T cell rabbit immunoglobulin. At present, domestic research on anti-human T cell immunoglobulin is mainly focused on anti-human T cell pig immunoglobulin, while research on anti-human T cell rabbit immunoglobulin is very little, and the anti-human T cell rabbit immunoglobulin on the market mainly depends on import and has extremely high price. In recent years, research shows that the anti-human T cell rabbit immunoglobulin has better application effect in preventing graft versus host reaction of bone marrow transplantation, so that independent development of a preparation process of the anti-human T cell rabbit immunoglobulin has important significance.
The invention patent with publication number CN112111004A discloses a production process of immunoglobulin, which comprises inactivating complement with SPF rabbit serum, precipitating with octanoic acid to obtain clarified liquid, and sequentially passing the clarified liquid through the following chromatography: affinity chromatography, anion exchange chromatography and anti-A/anti-B chromatography, and finally obtaining the immunoglobulin product with high yield and purity. This method has at least the following problems: (1) The octanoic acid precipitation is easy to cause harm to human bodies, and residues such as aluminum ions and the like can exist when a filter aid (such as diatomite) is used, so that adverse reactions are easy to cause in clinic; (2) The ligand in the anti-A/anti-B chromatographic packing has the problem of easy falling off, and the potential risk of causing clinical adverse reaction can also exist; (3) it is inconvenient for automation control and industrialization.
Disclosure of Invention
Based on the above, the invention provides a new preparation method of anti-human T cell rabbit immunoglobulin, which can overcome the problems existing in the prior art and successfully prepare the anti-human T cell rabbit immunoglobulin meeting the standard requirements of anti-human T cell rabbit immunoglobulin of the current edition of Chinese pharmacopoeia, each theory, and is convenient for industrialized implementation.
The invention realizes the technical purposes through the following technical proposal: a method for preparing anti-human T cell rabbit immunoglobulin, comprising the following steps:
s1, obtaining rabbit plasma/serum immunized by human peripheral blood T lymphocytes and/or thymus cells;
s2, placing the mixture at the temperature of not higher than 37 ℃ to melt slurry;
s3, adding healthy human blood plasma into the rabbit blood plasma or serum after the plasma melting to obtain a feed liquid A; adding hydroformylation human red blood cells into the feed liquid A, adjusting the pH value to 7.0+/-1.0, keeping the reaction temperature at 0-8 ℃, separating the red blood cells after full reaction, and collecting supernatant B; adding an aldehyde human placenta into the supernatant B, adjusting the pH to 7.0+/-1.0, keeping the reaction temperature at 0-8 ℃, separating placenta slag after full reaction, and collecting the supernatant C;
s4, adjusting the pH value of the supernatant C to 6.0+/-1.0, performing deep filtration, performing first ion exchange chromatography by adopting a phosphate buffer system with the pH value of 6.0+/-1.0, and collecting the flow-through liquid D;
s5, filtering the flow-through liquid D, adjusting the concentration to 10-30 mg/mL, loading the flow-through liquid D on an affinity chromatography column, washing the flow-through liquid D by an acetate buffer system with the pH value of 4.0+/-1.0, and collecting an eluent E;
s6, filtering and sterilizing the eluent E, and incubating at 24+/-2 ℃ to obtain a solution F;
s7, regulating the pH value of the solution F to 6.0+/-1.0, performing ion exchange chromatography for the second time, and collecting the flow-through liquid G to obtain a product containing anti-human T cell rabbit immunoglobulin.
As a preferred embodiment, the method further comprises the steps of:
s8, ultrafiltration displacement is carried out on the passing liquid G by adopting physiological sodium chloride solution, the pH value is regulated to 4.0+/-0.5, glycine is added to obtain a semi-finished product with the protein mass concentration of 1-3% and the glycine concentration of 10-30G/L, a 20nm virus-removing filter membrane is adopted to filter virus, and then virus-removing feed liquid is sterilized;
s9, sub-packaging the semi-finished product to obtain the finished product.
In a preferred embodiment, in step S2, the amount of healthy human plasma added is 1 to 5% of the amount of rabbit plasma added; in the step S5, the addition amount of the hydroformylation human red blood cells is 15-30% of the pulp addition amount, and the addition amount of the hydroformylation human placenta is 15-30% of the pulp addition amount.
As a preferred embodiment, the hydroformylation human placenta in the step S5 is prepared by hydroformylation reaction of a hydroformylation solution having a formaldehyde content of 0.8% -3% for 3-7 hours.
As a preferred embodiment, the method for preparing the hydroformylation human placenta comprises the following steps: obtaining human placenta dregs with negative endotoxin detection, and thawing; placing the unfrozen human placenta slag into placenta aldehyde liquid for carrying out an aldehyde reaction for 3-7 h, wherein the placenta aldehyde liquid is phosphate buffer solution containing 0.8% -3% formaldehyde; transferring the aldehyde placenta into a sodium chloride solution with physiological concentration for washing, transferring into a neutralization solution for neutralization reaction, wherein the neutralization solution is a glycine-containing sodium chloride solution, washing again, and drying by control to obtain the aldehyde human placenta.
As a preferred embodiment, the placental hydroformylation solution is a phosphate buffer solution containing 1% formaldehyde.
As a preferred embodiment, the pore size of the filter membrane used in the depth filtration in the steps S4 and S5 is 0.45. Mu.m.
In a preferred embodiment, the method for obtaining rabbit plasma in step S1 is as follows: the preparation method comprises the steps of mixing thymus cells and lymphocytes to immunize rabbits, and then collecting blood; wherein, the immunization program is as follows: performing primary immunization by subcutaneous multipoint injection at back, performing secondary boost immunization by intravenous injection or subcutaneous immunization at intervals of 14 days, and taking blood plasma 21 days after the secondary immunization.
The invention also aims to provide the anti-human T cell rabbit immunoglobulin prepared by the method, wherein the protein content is 10-30 g/L, the pH value is 4.0+/-0.2, the purity of P-ATG is not lower than 95% of the total protein, the sum of IgG monomer and dimer content is not lower than 95.0%, the polymer content is not higher than 5.0%, the E rose ring formation inhibition test titer is not lower than 1:4000, the lymphotoxin test titer is not lower than 1:2000, the anti-A and anti-B hemagglutinin is not higher than 1:64, the human platelet antibody is not higher than 1:4, the human plasma protein antibody and human plasma have no precipitation line, and the protein A residue is not higher than 0.001% of the total protein.
The preparation method of the anti-human T cell rabbit immunoglobulin provided by the invention comprises the steps of firstly adding healthy human blood into rabbit immune plasma, then utilizing the hydroformylation human red blood cells and the hydroformylation human placenta to absorb the hybrid antibodies, and finally sequentially carrying out treatments such as ion exchange chromatography, affinity chromatography, low pH incubation, ion exchange chromatography, ultrafiltration dialysis, virus removal and the like, thereby obtaining the anti-human T cell rabbit immunoglobulin, wherein the preparation method at least has the following advantages:
(1) The three-step chromatography process is adopted, a low-temperature ethanol process is not adopted, a low-temperature environment is not needed, the energy consumption is low, the safety is realized, the environmental pollution risk is low, the process continuity is good, the digitization and the automatic control can be better realized, and the amplified production can be realized;
(2) The hybrid antibody absorption process is more comprehensive, so that the impurities with larger clinical influence such as anti-erythrocyte antibodies, anti-basement membrane antibodies, anti-plasma protein antibodies and the like can be comprehensively reduced, and the clinical safety is better;
(3) The low pH incubation process for inactivating viruses is more strict, so that various viruses can be effectively inactivated, and the biological load of the viruses is reduced;
(4) The method has the advantages that the method is free of octanoic acid precipitation and the like, is easy to generate operation of diving in the sea for human bodies, has better protection for personnel, is free of filter aid (diatomite) and the like, and avoids residues of impurities such as aluminum ions and the like, so that adverse reactions caused by the substances in clinical practice are avoided;
(5) The method can be used for separating and extracting the blood plasma and serum, and has wider separation coverage range;
(6) The prepared anti-human T cell rabbit immunoglobulin can meet the standard requirement of anti-human T cell rabbit immunoglobulin of each theory of the current edition of Chinese pharmacopoeia, the purity (monomer and dimer) of the final finished product can reach 100 percent, and the purity is basically no obvious impurity and is far higher than the standard of more than 90 percent of the current edition of Chinese pharmacopoeia, and 1 bottle of anti-human T cell rabbit immunoglobulin (25 mg/bottle) can be prepared by per 2-3ml of immune rabbit plasma.
Drawings
FIG. 1 is a graph of the average mortality analysis of complement-mediated lymphocytes in example 1;
FIG. 2 is a graph of percent pass analysis of complement-mediated lymphocytotoxicity in example 1;
FIG. 3 is a chart showing molecular size analysis of the affinity eluate of the first sample in example 2;
FIG. 4 is a chart showing molecular size analysis of the affinity eluate of the second sample in example 2;
FIG. 5 is a molecular size analysis chart of the affinity eluate of the third sample in example 2;
FIG. 6 is a chart showing the molecular size analysis of the second ion exchange chromatography flow-through of the first sample in example 2;
FIG. 7 is a chart showing the molecular size analysis of a second ion exchange chromatography flow-through for a second sample of example 2;
FIG. 8 is a chart showing molecular size analysis of a second ion exchange chromatography flow-through for a third sample of example 2;
FIG. 9 is a graph showing the detection criteria of protein A in example 2.
Detailed Description
The present invention will be described in further detail with reference to specific examples so as to more clearly understand the present invention by those skilled in the art. The following examples are given for illustration of the invention only and are not intended to limit the scope of the invention. All other embodiments obtained by those skilled in the art without creative efforts are within the protection scope of the present invention based on the specific embodiments of the present invention.
In the examples of the present invention, all raw material components are commercially available products well known to those skilled in the art unless specified otherwise; in the embodiments of the present invention, unless specifically indicated, all technical means used are conventional means well known to those skilled in the art.
The reagents used in the examples of the present invention are all commercially available, without specific explanation. The experimental procedure, which does not address the specific conditions in the examples below, is generally followed by conventional conditions, such as molecular cloning, as described in Sambrook et al: conditions described in the laboratory Manual (New York: coldSpring Harbor Laboratory Press, 1989) or as recommended by the manufacturer.
Example 1
The embodiment provides a method for obtaining anti-human T cell rabbit immunoglobulin plasma, which comprises the following steps:
(1) Preparation of antigen:
preparation of thymus cell immunogen: taking the waste thymus cells from the surgery, grinding and washing in a biosafety cabinet, and preparing into 7-10 multiplied by 10 by using physiological saline 7 After antigen epitope detection by a flow type detection analyzer, carrying out subsequent immunization according to the ratio of 7-10 multiplied by 10 7 The amount of immune cells per cell was kept.
Preparation of peripheral T lymphocyte immunogens: taking medical waste leukocyte filter disc, backflushing the leukocyte filter disc with 0.9% physiological saline in a biosafety cabinet, collecting backflushed saline containing leukocytes with a sterile bottle, separating mononuclear cells with lymphocyte separating liquid to obtain mononuclear cells with higher purity according to 1×10 7 Culture was performed at a density of/mL, and culture was performed using commercial lymphocyte serum-free medium. The lymphocytes obtained by proliferation culture were collected by centrifugation at 1500rpm for 5min, washed with 0.9% NaCl physiological saline 2 to 3 times, counted by a cell counter, and analyzed by flow assay for epitopes. The antigen cell amount was prepared according to the body weight of healthy rabbits and the antigen cell amount was 7 to 10X 10 7 The amount of immune cells per cell was kept.
And respectively adding a mineral oil molecular adjuvant into the two cell antigens, taking out the mineral oil molecular adjuvant and the antigens under the aseptic condition, rapidly and uniformly mixing according to the mass ratio of 1:1, and vibrating for 10-20 minutes to form the oil-in-water antigen.
(2) Animal experiment:
the antigen prepared above is immunized with New Zealand white rabbits, and multi-point subcutaneous injections are carried out on both sides of the nape of the neck of the rabbits. Immunization program set 8 experimental groups and 1 blank group, 5 blank groups, 10 blank groups, and different immune antigens were set simultaneously for comparison study, and the specific table 1 is shown below. Groups 7 and 8 were immunized with thymocytes for the first time and boosted with peripheral T lymphocytes. The first immunization was followed by a 2 nd boost, which was administered by intravenous injection and subcutaneous immunization, respectively, 14 days and 21 days apart, and the last boost was followed by subcutaneous multipoint injection 21 days after the second immunization. The blood sampling detection titers are carried out before and after basic immunization and secondary immunization, the blood sampling is carried out once every 3 days after the last booster immunization, the fluctuation level of the antibody titer within 12 days is continuously monitored, and all blood sampling treatment is carried out for 14 days.
Table 1 immunization protocol formulation
(3) Potency detection
The collected rabbit serum was analyzed for antibody titer by lymphotoxin assay. The detailed description of lymphocyte toxicity test is described in the fourth part of the pharmacopoeia of 2020 edition (general rule 3516). Titers were detected and analyzed 14 days, 21 days after the second, and 3 days, 6 days, 9 days, 12 days after the third, and the results are shown in tables 2, 3 and fig. 1, 2:
TABLE 2 complement-mediated average mortality analysis of lymphotoxin
TABLE 3 complement mediated lymphocyte toxicity pass rate analysis
From the above results, it can be seen that: the lymphocyte immunized group thymus and cell mixed immunized group (i.e., experimental groups 7 and 8) were longer in potency duration and relatively stable, with the highest potency 21 days after the second immunization.
(4) Preparation of immune plasma
Immunization was performed in the manner of immunization of experimental groups 7 and 8, and immune plasma was obtained.
Example 2
The embodiment provides a preparation method of rabbit anti-human T cell immunoglobulin, which comprises the following steps:
s1, preparing immune rabbit plasma: human lymphocytes separated from human thymus cells or healthy human blood are used for immunizing healthy rabbits according to the immunization mode of the experimental groups 7 and 8 in the example 1, and immune rabbit plasma is collected and separated after the test is qualified.
S2, combining and melting plasma: mixing the thawed immune rabbit plasma according to the requirement of throwing the plasma, and placing the mixture into a plasma melting state under the condition of not higher than 37 ℃ to obtain the mixed rabbit plasma.
S3, absorbing hybrid antibody by healthy human blood plasma: adding healthy human plasma into the mixed rabbit plasma, wherein the adding amount of the healthy human plasma is 1-5% of the adding amount of the rabbit plasma, so as to obtain a feed liquid A; adding hydroformylation human red blood cells into the feed liquid A, adjusting the pH value to 7.0+/-1.0, keeping the reaction temperature at 0-8 ℃, stirring for at least 6 hours, press-filtering to separate the red blood cells, and collecting supernatant B; adding the hydroformylation human placenta into the supernatant B, adjusting the pH to 7.0+/-1.0, keeping the reaction temperature at 0-8 ℃, stirring for at least 6 hours, press-filtering to separate placenta slag, and collecting supernatant C;
wherein, the preparation method of the hydroformylation human placenta comprises the following steps: obtaining processed human placenta slag with negative endotoxin detection, and thawing; draining the thawed human placenta slag, placing the human placenta slag into placenta aldehyde liquid, wherein the placenta aldehyde liquid is phosphate buffer solution containing 0.8% -3% formaldehyde, and the ratio of the liquid to the solid is 1:2-1:5, and carrying out aldehyde reaction for 3-7 h; transferring the placenta after the hydroformylation reaction into a sodium chloride solution with physiological concentration, stirring for 10-30 min, and drying; transferring the washed aldehyde placenta into a neutralization solution, wherein the neutralization solution is sodium chloride solution containing 0.5% -2% glycine, and the material-liquid ratio is 1:2-1:5, and carrying out neutralization reaction for 1-3 h; transferring the neutralized placenta into a sodium chloride solution with physiological concentration, stirring for 10-30 min, and drying to obtain the aldehyde placenta.
S4, performing first ion exchange chromatography: the pH of the supernatant C was adjusted to 6.0.+ -. 1.0, and after depth filtration (0.45 μm), the supernatant was subjected to a first ion exchange chromatography using a phosphate buffer system, washed with a phosphate buffer solution having a pH of 6.0.+ -. 1.0, and the flow-through D was collected.
S5, affinity chromatography: the flow-through solution D was filtered (0.45 μm) and the concentration was adjusted to 10 to 30mg/mL, applied to an affinity column, and the eluate E was collected using an acetate buffer system having a pH of 4.0.+ -. 1.0.
S6, virus inactivation and removal: filtering and sterilizing the eluent F, and incubating at 24+/-2 ℃ for 24 days to obtain a solution F.
S7, performing ion exchange chromatography for the second time: and (3) regulating the pH value of the solution F to 6.0+/-1.0, loading the solution F on an ion exchange chromatographic column, adding phosphate buffer solution with the pH value of 6.0+/-1.0 for washing, and collecting the flow-through liquid H.
S8, preparing a semi-finished product: the physiological sodium chloride solution is adopted to carry out ultrafiltration displacement on the flow-through liquid H, the pH value is regulated to 4.0+/-0.5, glycine is added to obtain a semi-finished product with the protein concentration of 1-3% and the glycine content of 10-30 g/L, a 20nm virus-removing filter membrane is adopted to filter and remove viruses, and then the virus-removing feed liquid is subjected to sterilization operation.
S9, verification and split charging: sampling, identifying the semi-finished product, and sub-packaging the semi-finished product into a medium boron silcillin bottle, wherein the sub-packaging amount is 1 mL/bottle, thus obtaining the R-ATG finished product.
2.1 according to the corresponding detection items and standards of the finished product of the anti-human T cell rabbit immunoglobulin of each theory of the current edition of Chinese pharmacopoeia, the finished product of the anti-human T cell rabbit immunoglobulin preparation prepared according to the method is detected, and the result is as follows:
the protein content is 10-30 g/L, the pH value is 4.0+/-0.2, the purity of the P-ATG is not lower than 95% of the total protein, the sum of the content of IgG monomers and dimer is not lower than 95.0%, the content of multimer is not higher than 5.0%, the E rose ring formation inhibition test titer is not lower than 1:4000, the lymphotoxin test titer is not lower than 1:2000, the anti-A and anti-B hemagglutinin are not higher than 1:64, the human platelet antibody is not higher than 1:4, the human plasma protein antibody and human plasma have no precipitation line, and the protein A residue is not higher than 0.001% of the total protein.
2.1 Process study
(1) Results of first ion exchange chromatography of samples of a batch in pilot experiments
TABLE 4 results of first ion exchange chromatography for a batch of samples
(2) The yields and purification of the affinity chromatography and the second ion exchange chromatography were studied in pilot experiments at different loading levels, and the results are shown in fig. 3 to 8 and table 5 below:
TABLE 5 yields and purification results of affinity chromatography and ion exchange chromatography under different loading conditions
From the above results, it can be seen that: the process has good stability, the purity (monomer and dimer) of the final product can reach 100 percent, and the product basically has no obvious impurity and is far higher than the standard of more than 90 percent of the current edition of Chinese pharmacopoeia.
(3) Protein a residue detection: protein A residue detection was performed on the material collected by the affinity and second ion exchange chromatography in the pilot experiment, and the results are shown in FIG. 9 and the following tables 6 and 7:
TABLE 6 detection and analysis of protein A residues in samples from various purification stages
TABLE 7 protein A residual detection fit standard curve equation
| Curve name | Curve formula | A | B | C | D | R 2 |
| Standard curve | Y＝(A-D)/(1+(X/C)^B)+D | 0.0318 | 1.13 | 10.1 | 26.2 | 0.986 |
Therefore, after the second ion exchange chromatography treatment, the method provided by the invention has the advantages that the fallen protein A is not detected in the final finished product (ion flow through liquid), the requirement that the residual amount of the protein A is not higher than 0.001% (10 ppm) of the total amount of protein in Chinese pharmacopoeia is completely met, and the method provided by the invention is reliable and good in repeatability.
It should be noted that the above examples are only for further illustrating and describing the technical solution of the present invention, and are not intended to limit the technical solution of the present invention, and the method of the present invention is only a preferred embodiment and is not intended to limit the scope of the present invention. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (9)
1. A method for preparing anti-human T cell rabbit immunoglobulin, which is characterized by comprising the following steps:
s1, obtaining rabbit plasma or serum immunized by human peripheral blood T lymphocytes and/or thymus cells;
s2, placing the mixture at the temperature of not higher than 37 ℃ to melt slurry;
s3, adding healthy human blood plasma into the rabbit blood plasma or serum after the plasma melting to obtain a feed liquid A; adding hydroformylation human red blood cells into the feed liquid A, adjusting the pH value to 7.0+/-1.0, keeping the reaction temperature at 0-8 ℃, separating the red blood cells after full reaction, and collecting supernatant B; adding aldehyde human placenta dregs into the supernatant B, adjusting the pH to 7.0+/-1.0, keeping the reaction temperature at 0-8 ℃, separating the placenta dregs after full reaction, and collecting the supernatant C;
s4, adjusting the pH value of the supernatant C to 6.0+/-1.0, performing deep filtration, performing first ion exchange chromatography by adopting phosphate buffer solution with the pH value of 6.0+/-1.0, and collecting the flow-through liquid D;
s5, filtering the flow-through liquid D, adjusting the protein concentration to 10-30 mg/mL, loading the solution on an affinity chromatography column, washing the solution by an acetate buffer system with the pH value of 4.0+/-1.0, and collecting an eluent E;
s6, filtering and sterilizing the eluent E, and incubating at 24+/-2 ℃ to obtain a solution F;
s7, regulating the pH value of the solution F to 6.0+/-1.0, performing ion exchange chromatography for the second time, and collecting the flow-through liquid G to obtain a product containing anti-human T cell rabbit immunoglobulin.
2. The method for preparing anti-human T cell rabbit immunoglobulin according to claim 1, further comprising the steps of:
s8, ultrafiltration displacement is carried out on the passing liquid G by adopting physiological sodium chloride solution, the pH value is regulated to 4.0+/-0.5, glycine is added to obtain a semi-finished product with the protein mass concentration of 1-3% and the glycine concentration of 10-30G/L, a 20nm virus-removing filter membrane is adopted to filter virus, and then virus-removing feed liquid is sterilized;
s9, sub-packaging the semi-finished product to obtain the finished product.
3. The method for producing anti-human T cell rabbit immunoglobulin according to claim 1 or 2, wherein in step S2, the amount of healthy human plasma added is 1 to 5% of the amount of rabbit plasma added; in the step S5, the addition amount of the hydroformylation human red blood cells is 15-30% of the pulp addition amount, and the addition amount of the hydroformylation human placenta is 15-30% of the pulp addition amount.
4. The method for preparing anti-human T cell rabbit immunoglobulin according to claim 1, wherein the hydroformylation human placenta in step S5 is prepared by hydroformylation reaction of an hydroformylation solution with formaldehyde content of 0.8% -3% for 3-7 hours.
5. The method of claim 4, wherein the method of preparing the hydroformylation human placenta comprises the steps of: obtaining human placenta dregs with negative endotoxin detection, and thawing; placing the unfrozen human placenta slag into placenta aldehyde liquid for carrying out an aldehyde reaction for 3-7 h, wherein the placenta aldehyde liquid is phosphate buffer solution containing 0.8% -3% formaldehyde; transferring the aldehyde placenta into a sodium chloride solution with physiological concentration for washing, transferring into a neutralization solution for neutralization reaction, wherein the neutralization solution is a glycine-containing sodium chloride solution, washing again, and drying by control to obtain the aldehyde human placenta.
6. The method for preparing anti-human T cell rabbit immunoglobulin according to claim 5, wherein the placental hydroformylation solution is phosphate buffer solution containing 1% formaldehyde.
7. The method for preparing anti-human T cell rabbit immunoglobulin according to claim 1, wherein the pore size of the filter membrane used in the depth filtration in the steps S4 and S5 is 0.45. Mu.m.
8. The method for preparing anti-human T cell rabbit immunoglobulin according to claim 1, wherein the method for obtaining rabbit plasma in step S1 comprises the steps of: the preparation method comprises the steps of mixing thymus cells and lymphocytes to immunize rabbits, and then collecting blood; wherein, the immunization program is as follows: performing primary immunization by subcutaneous multipoint injection at back, performing secondary boost immunization by intravenous injection or subcutaneous immunization at intervals of 14 days, and taking blood plasma 21 days after the secondary immunization.
9. The anti-human T cell rabbit immunoglobulin prepared by the method of any one of claims 1-8, wherein the protein content is 10-30 g/L, the pH value is 4.0+ -0.2, the purity of P-ATG is not lower than 95% of the total protein, the sum of IgG monomer and dimer content is not lower than 95.0%, the multimer content is not higher than 5.0%, the E rose ring formation inhibition test titer is not lower than 1:4000, the lymphotoxin test titer is not lower than 1:2000, the anti-A and anti-B hemagglutinin is not higher than 1:64, the human platelet antibody is not higher than 1:4, the human plasma protein antibody and human plasma have no precipitation line, and the protein A residue is not higher than 0.001% of the total protein.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311241053.8A CN117069836A (en) | 2023-09-22 | 2023-09-22 | Preparation method of anti-human T cell rabbit immunoglobulin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311241053.8A CN117069836A (en) | 2023-09-22 | 2023-09-22 | Preparation method of anti-human T cell rabbit immunoglobulin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117069836A true CN117069836A (en) | 2023-11-17 |
Family
ID=88706208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311241053.8A Pending CN117069836A (en) | 2023-09-22 | 2023-09-22 | Preparation method of anti-human T cell rabbit immunoglobulin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117069836A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101084923A (en) * | 2007-06-22 | 2007-12-12 | 岳阳博康生物技术有限公司 | Method for preparing rabbit against human T lymphocytes immune serum |
| CN101570576A (en) * | 2009-06-08 | 2009-11-04 | 王太林 | Method for preparing antihuman lymphocyte antibodies |
| US20100330071A1 (en) * | 2009-05-27 | 2010-12-30 | Baxter International Inc. | Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use |
| US20170073396A1 (en) * | 2014-03-11 | 2017-03-16 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Method for preparing human plasma proteins |
| CN112111004A (en) * | 2020-08-27 | 2020-12-22 | 成都生物制品研究所有限责任公司 | Production process of rabbit immunoglobulin |
| CN115232783A (en) * | 2022-08-03 | 2022-10-25 | 武汉中生毓晋生物医药有限责任公司 | Preparation method of anti-human T cell pig immunoglobulin and hydroformylation placenta |
-
2023
- 2023-09-22 CN CN202311241053.8A patent/CN117069836A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101084923A (en) * | 2007-06-22 | 2007-12-12 | 岳阳博康生物技术有限公司 | Method for preparing rabbit against human T lymphocytes immune serum |
| US20100330071A1 (en) * | 2009-05-27 | 2010-12-30 | Baxter International Inc. | Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use |
| CN101570576A (en) * | 2009-06-08 | 2009-11-04 | 王太林 | Method for preparing antihuman lymphocyte antibodies |
| US20170073396A1 (en) * | 2014-03-11 | 2017-03-16 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Method for preparing human plasma proteins |
| CN112111004A (en) * | 2020-08-27 | 2020-12-22 | 成都生物制品研究所有限责任公司 | Production process of rabbit immunoglobulin |
| CN115232783A (en) * | 2022-08-03 | 2022-10-25 | 武汉中生毓晋生物医药有限责任公司 | Preparation method of anti-human T cell pig immunoglobulin and hydroformylation placenta |
Non-Patent Citations (2)
| Title |
|---|
| 余健等: "传代人淋巴细胞免疫猪的免疫效果初探", 微生物学免疫学进展, vol. 47, no. 6, 14 November 2019 (2019-11-14), pages 47 - 51 * |
| 曹澍泽等: "兽医微生物学及免疫学技术", 31 May 1992, 北京农业大学出版社, pages: 288 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Iwasaki et al. | The preparation and testing of horse antidog and antihuman antilymphoid plasma or serum and its protein fractions | |
| Miller et al. | Phylogeny of lymphocyte heterogeneity: the cellular requirements for the mixed leucocyte reaction with channel catfish. | |
| KR102306419B1 (en) | Sterile chromatography resin and use thereof in manufacturing processes | |
| CN101790382A (en) | idiotypic vaccine | |
| JP2018503620A (en) | Methods for purifying recombinant proteins | |
| TW201509432A (en) | Matrix of affinity chromatography | |
| TW202043253A (en) | A continuous manufacturing process for biologics manufacturing by integration of drug substance and drug product processes | |
| KR20210049155A (en) | Sterile chromatography resin and its use in manufacturing processes | |
| US8394368B2 (en) | Method for producing a composition for promoting survival of transplanted hematopoietic stem cell | |
| CN112111004B (en) | Production process of rabbit immunoglobulin | |
| CN112225799B (en) | Method for rapidly extracting blood plasma of COVID-19 patient in recovery period by automatic separation system | |
| CN112010968B (en) | Method for rapidly extracting blood plasma of patient with COVID-19 in convalescence stage for preparing immunoglobulin G | |
| AU2009244617A1 (en) | IRX-2 modified manufacturing process | |
| CN117069836A (en) | Preparation method of anti-human T cell rabbit immunoglobulin | |
| CN107964044B (en) | Method for purifying anti-CD 20 monoclonal antibody from milk sample | |
| WO1994000561A1 (en) | Human monoclonal anti-rhesus (d) antibodies and cell lines producing same | |
| CN115232783B (en) | Preparation method of anti-human T cell pig immunoglobulin and hydroformylation placenta | |
| MX2011006608A (en) | Systems and methods for obtaining immunoglobulin from blood. | |
| CA2949994A1 (en) | Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus | |
| CN110872345B (en) | Preparation method of high-purity immunoglobulin G | |
| CN111471101A (en) | Method for removing residual IgA in human immunoglobulin products | |
| CN110452881A (en) | Using CD4 as the preparation and application of the antibody of target spot and CAR-T cell | |
| KR20150084836A (en) | Method of isolating synagis® in the absence of benzonase | |
| EP0340002B1 (en) | A human-human hybridoma derived monoclonal antibody, and the use thereof | |
| Hsu | Circulating Lymphocyte Inhibitors in Liver Diseases and Uremia: Concept of Humoral Immunoregulation and Technical Factors in Inhibitor Assays |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |